Shionogi's naldemedine performs well in first COMPOSE Phase III
This article was originally published in Scrip
Executive Summary
Shionogi's naldemedine (S-297995), an investigational peripherally acting mu-opioid receptor antagonist, has met primary and secondary endpoints in a phase III study for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain receiving opioid therapy.